Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 3,66 MB, PDF-dokument
People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mor-tality. Recent clinical trials support new approaches to treat diabetes and CKD. The 2022 American Diabetes Association (ADA) Standards of Medical Care in Diabetes and the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease each provide evidence-based recommendations for management. A joint group of ADA and KDIGO representatives reviewed and developed a series of consensus statements to guide clinical care from the ADA and KDIGO guidelines. The published guidelines are aligned in the areas of CKD screening and diagnosis, glycemia mon-itoring, lifestyle therapies, treatment goals, and pharmacologic management. Recommendations include comprehensive care in which pharmacotherapy that is proven to improve kidney and cardiovascular outcomes is layered on a foundation of healthy lifestyle. Consensus statements provide specific guidance on use of renin-angiotensin system inhibitors, metformin, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal miner-alocorticoid receptor antagonist. These areas of consensus provide clear direction for implementation of care to improve clinical outcomes of people with diabetes and CKD.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Diabetes Care |
| Vol/bind | 45 |
| Udgave nummer | 12 |
| Sider (fra-til) | 3075-3090 |
| ISSN | 0149-5992 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
Duality of Interest. I.H.d.B.’s employer receives research support from Dexcom, and he has received honoraria from the ADA. He is a consultant to or advisory board member of AstraZeneca, Bayer, Boehringer Ingelheim, Cy-clerion Therapeutics, George Clinical, Goldfinch Bio, and Ironwood Pharmaceuticals. He is also deputy editor for the Clinical Journal of the American Society of Nephrology. K.K.’s institution has received research grants from Boehringer Ingelheim, AstraZeneca, Novartis, Novo Nordisk, Sanofi, Lilly, and Merck Sharp & Dohme, and he is a consultant to Novo Nordisk, AstraZeneca, Sanofi, Servier, Merck Sharp & Dohme, Novartis, Abbott, Amgen, Bayer, Lilly, Roche, Berlin-Chemie AG/Menarini Group, and Boehringer Ingelheim. T.S.’s employer receives research support from Transplant House, and she has received honoraria from AstraZeneca. K.R.T. has received research grants from Goldfinch Bio, Bayer, and Travere Therapeutics. She is a consultant to or advisory board member of Eli Lilly, AstraZeneca, Boehringer Ingelheim, Gilead Sciences, Goldfinch Bio, Novo Nordisk, Bayer, and Travere Therapeutics. J.J.N. is an advisory board member for Novo Nordisk and Sanofi and is on Dexcom’s speakers bureau. C.M.R. has received a research grant from Dexcom and honoraria from AstraZeneca. She has also received funding from Fresenius Medical Care and ReCor Medical. S.E.R.’s employer receives research grants from Bayer, and she is a consultant to or advisory board member of Bayer, Relypsa, and Reata Pharmaceuticals. She is the president-elect of the National Kidney Foundation. P.R. has received research support from Novo Nordisk, AstraZeneca, Bayer,
Publisher Copyright:
© 2022 by American Diabetes Association, International Society of Nephrology, and KDIGO.
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
ID: 343128128